Skip to content

Take a closer look at the progress of our first-in-class therapeutics.

STAGE OF DEVELOPMENT
Program Indication
PRURITUS
Phase 1 Phase 2 Phase 3 Approved Commercial Rights
KORSUVA®
injection1
HD-CKD Commercial Rights: VFMCRP (ex-Japan
and S. Korea)2,3
VFMCRP (ex-Japan
and S. Korea)2,3
Oral difelikefalin Advanced NDD-CKD
(stages IV-V)
Commercial Rights: Cara Therapeutics
Cara Therapeutics
Oral difelikefalin Atopic Dermatitis Commercial Rights: Cara
Therapeutics
Cara
Therapeutics
Oral difelikefalin Notalgia Paresthetica Commercial Rights: Cara Therapeutics
Cara Therapeutics
Oral difelikefalin Primary Biliary Cholangitis Commercial Rights: Cara Therapeutics
Cara Therapeutics
  1. 1. Approved in the EU and UK with the tradename Kapruvia™.
  2. 2. Commercialization rights to difelikefalin in defined indications – Japan: Maruishi Pharmaceutical Co, LTD; South Korea: Chong Kun Dang Pharmaceuticals.
  3. 3. Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has commercial rights under a profit-share arrangement in the US and a royalty arrangement ex-US.
    HD-CKD: Hemodialysis Chronic Kidney Disease; NDD-CKD: Non-Dialysis Dependent Chronic Kidney Disease